Alteplase For
Acute Ischemic Stroke
Angde Biotech Pharmaceutical Co., Ltd.Phase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 65/ 100
Competitive context
211 Active assets in the Acute Ischemic Stroke cohort.
View all 50 →
Same molecule, other indications
Alteplase For is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →